1. Cell Cycle/DNA Damage Epigenetics Apoptosis
  2. Aurora Kinase Apoptosis
  3. Barasertib-HQPA

Barasertib-HQPA  (Synonyms: AZD2811; INH-34; AZD1152-HQPA)

製品番号: HY-10126 純度: 98.90%
COA 取扱説明書 Technical Support

Barasertib-HQPA (AZD2811) is a highly selective Aurora B inhibitor with an IC50 of 0.37 nM in a cell-free assay. Barasertib-HQPA (AZD2811) induces growth arrest and apoptosis in cancer cells.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 722544-51-6

容量 価格(税別) 在庫状況 数量
>無料サンプル (0.1 - 0.2 mg)   今すぐ申し込む  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
USD 61 在庫あり
Solution
10 mM * 1 mL in DMSO USD 61 在庫あり
Solid
5 mg $55 在庫あり
10 mg $77 在庫あり
25 mg $175 在庫あり
50 mg $319 在庫あり
100 mg $572 在庫あり
200 mg   お問い合わせ  
500 mg   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 9 publication(s) in Google Scholar

Other Forms of Barasertib-HQPA:

Top Publications Citing Use of Products

    Barasertib-HQPA purchased from MedChemExpress. Usage Cited in: J Cell Sci. 2025 Sep 1:jcs.263766.  [Abstract]

    Confocal images of microtubule dynamics in control extracts (top row) and extracts with 40 µM Aurora kinase B inhibitor Barasertib-HQPA (bottom row). n=6. Each image is a maximum-intensity projection of nine confocal planes spanning 16 µm of depth. Imaging started at an arbitrary time point when asters had just begun to form in the untreated extracts. The results showed that Aurora kinase B inhibition by Barasertib-HQPA abolishes the aster, and the cell-like compartments form with a substantial delay.

    Barasertib-HQPA purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2022 Jan 11;23(2):763.

    MCD4 were left untreated or treated with DMSO (0.3% or 0.2%, 1 h), Alisertib (AURKA inhibitor; 30 µM or 20 µM, 1 h), or Barasertib-HQPA (AURKB inhibitor; 30 µM or 20 µM, 1 h) alone or in combination with forskolin (Fsk; 30 µM, 30 min) or arginine-vasopressin (AVP; 100 nM, 30 min) where indicated. AQP2 was detected by immunofluorescence microscopy. Shown are representative images of four independent experiments; scale bar 30 µm. AQP2 was quantified using a segmentation-based approach. Ratios > 1 indicate a predominant localization at the plasma membrane.

    Barasertib-HQPA purchased from MedChemExpress. Usage Cited in: Exp Cell Res. 2021 Sep 1;406(1):112741.  [Abstract]

    The IC50 of AURKB inhibitors (AZD1152-HQPA (Barasertib-HQPA, 48 h) and hesperadin) was explored by CCK-8 in gastric cancer cells (MGC-803 and SGC-7901).

    Barasertib-HQPA purchased from MedChemExpress. Usage Cited in: Ann Transl Med. 2020 May;8(10):646.  [Abstract]

    The effect of AURKB inhibitor (AZD1152 (Barasertib)-HQPZ (10 μM; 48 h) and hesperidin) on Caki-1 and 786-0 cells with ALKBH5 overexpression was measured by CCK8 and clone formation assays. The colony fold (NC/ALKBH5) is stated under the histogram.

    Aurora Kinase アイソフォーム固有の製品をすべて表示:

    • 生物活性

    • 純度とドキュメンテーション

    • 参考文献

    • カスタマーレビュー

    製品説明

    Barasertib-HQPA (AZD2811) is a highly selective Aurora B inhibitor with an IC50 of 0.37 nM in a cell-free assay. Barasertib-HQPA (AZD2811) induces growth arrest and apoptosis in cancer cells[1].

    IC50 & Target[1]

    Aurora B

    0.37 nM (IC50)

    Cellular Effect
    Cell Line Type Value Description References
    A549 IC50
    0.1 μM
    Compound: AAZD1152-HQPA
    Cytotoxicity against human A549 cells by SRB assay
    Cytotoxicity against human A549 cells by SRB assay
    [PMID: 25036791]
    A549 IC50
    5.4 μM
    Compound: AAZD1152-HQPA
    Antimigratory activity against human A549 cells assessed as inhibition of cell migration after 8 to 24 hrs by transwell migration assay
    Antimigratory activity against human A549 cells assessed as inhibition of cell migration after 8 to 24 hrs by transwell migration assay
    [PMID: 25036791]
    A549 IC50
    8.3 μM
    Compound: AAZD1152-HQPA
    Antimigratory activity against human A549 cells assessed as inhibition of cell migration after 8 to 24 hrs by scratch wound model assay
    Antimigratory activity against human A549 cells assessed as inhibition of cell migration after 8 to 24 hrs by scratch wound model assay
    [PMID: 25036791]
    HL-60 IC50
    12.7 nM
    Compound: AZD1152
    Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by MTT assay
    [PMID: 25089810]
    HepG2 IC50
    0.1 μM
    Compound: AAZD1152-HQPA
    Cytotoxicity against human HepG2 cells by SRB assay
    Cytotoxicity against human HepG2 cells by SRB assay
    [PMID: 25036791]
    MOLM-13 IC50
    1 nM
    Compound: AZD1152-HQPA
    Inhibition of clonogenic growth in human MOLM-13 cells incubated for 10 days
    Inhibition of clonogenic growth in human MOLM-13 cells incubated for 10 days
    [PMID: 17495131]
    MOLM-13 IC50
    12 nM
    Compound: AZD1152-HQPA
    Inhibition of cell proliferation of human MOLM-13 cells incubated for 48 hrs by 3H-thymidine uptake assay
    Inhibition of cell proliferation of human MOLM-13 cells incubated for 48 hrs by 3H-thymidine uptake assay
    [PMID: 17495131]
    MOLM-13 IC50
    9.7 nM
    Compound: AZD1152
    Cytotoxicity against human MOLM13 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human MOLM13 cells assessed as cell viability after 48 hrs by MTT assay
    [PMID: 25089810]
    MV4-11 IC50
    2.8 nM
    Compound: AZD1152-HQPA
    Inhibition of clonogenic growth in human MV4-11 cells incubated for 10 days
    Inhibition of clonogenic growth in human MV4-11 cells incubated for 10 days
    [PMID: 17495131]
    MV4-11 IC50
    8 nM
    Compound: AZD1152-HQPA
    Inhibition of cell proliferation of human MV4-11 cells incubated for 48 hrs by 3H-thymidine uptake assay
    Inhibition of cell proliferation of human MV4-11 cells incubated for 48 hrs by 3H-thymidine uptake assay
    [PMID: 17495131]
    MV4-11 IC50
    8.6 nM
    Compound: AZD1152
    Cytotoxicity against human MV4-11 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human MV4-11 cells assessed as cell viability after 48 hrs by MTT assay
    [PMID: 25089810]
    SW-620 IC50
    0.017 μM
    Compound: 7, AZD-1152 HQPA
    Inhibition of aurora B in human SW620 cells assessed as inhibition of histone H3 phosphorylation
    Inhibition of aurora B in human SW620 cells assessed as inhibition of histone H3 phosphorylation
    [PMID: 19320489]
    THP-1 IC50
    25.1 nM
    Compound: AZD1152
    Cytotoxicity against human THP1 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human THP1 cells assessed as cell viability after 48 hrs by MTT assay
    [PMID: 25089810]
    体外実験

    Barasertib-HQPA (3 μM, 3 hours) significantly decreases expression of the phosphorylated forms of histone H3 in freshly isolated leukemia cells[1].
    Barasertib-hydroxyquinazoline pyrazol anilide (HQPA) is converted rapidly to the active Barasertib-HQPA in plasma[2].
    Barasertib-HQPA treatment induced defective cell survival, polyploidy, and cell death in LNCaP cell line[3].
    Barasertib-HQPA induces a marked anti-propliferative effect accompanied by the appearance of a polyploid population, which in most cases led to apoptosis[4].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Proliferation Assay[1].

    Cell Line: AML lines (HL-60, NB4, MOLM13), ALL line (PALL-2), biphenotypic leukemia (MV4-11), acute eosinophilic leukemia (EOL-1), and the blast crisis of chronic myeloid leukemia K562 cells.
    Concentration: 0-100 nM. (Barasertib -HQPA)
    Incubation Time: 48 h.
    Result: IC50 values ranged from 3 nM to 40 nM.
    体内実験

    Barasertib-HQPA (AZD1152, 25 mg/kg) markedly suppresses the growth and weights of AZD1152-treated tumors[1].
    Barasertib-HQPA (AZD1152, 5 mg/kg) enhances the ability of vincristine or daunorubicin to inhibit the proliferation of human MOLM13 leukemic xenografts[1].
    Barasertib-HQPA (AZD1152, (10-150 mg/kg/d) potently inhibited the growth of human colon, lung, and hematologic tumor xenografts (mean tumor growth inhibition range, 55% to z100%; P < 0.05) in immunodeficient mice[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    臨床実験
    分子量

    507.56

    分子式

    C26H30FN7O3

    CAS 番号
    Appearance

    Solid

    Color

    White to yellow

    SMILES

    O=C(CC1=NNC(NC2=C3C=CC(OCCCN(CCO)CC)=CC3=NC=N2)=C1)NC4=CC=CC(F)=C4

    輸送条件

    Room temperature in continental US; may vary elsewhere.

    保管条件
    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    溶剤 & 溶解度
    体外: 

    DMSO : ≥ 22 mg/mL (43.34 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.9702 mL 9.8511 mL 19.7021 mL
    5 mM 0.3940 mL 1.9702 mL 3.9404 mL
    10 mM 0.1970 mL 0.9851 mL 1.9702 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます:C1V1 = C2V2

    濃度 (開始)

    C1

    ×
    体積 (開始)

    V1

    =
    濃度 (終了)

    C2

    ×
    体積 (終了)

    V2

    体内:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (4.93 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 2.5 mg/mL (4.93 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    純度とドキュメンテーション
    参考文献

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 1.9702 mL 9.8511 mL 19.7021 mL 49.2553 mL
    5 mM 0.3940 mL 1.9702 mL 3.9404 mL 9.8511 mL
    10 mM 0.1970 mL 0.9851 mL 1.9702 mL 4.9255 mL
    15 mM 0.1313 mL 0.6567 mL 1.3135 mL 3.2837 mL
    20 mM 0.0985 mL 0.4926 mL 0.9851 mL 2.4628 mL
    25 mM 0.0788 mL 0.3940 mL 0.7881 mL 1.9702 mL
    30 mM 0.0657 mL 0.3284 mL 0.6567 mL 1.6418 mL
    40 mM 0.0493 mL 0.2463 mL 0.4926 mL 1.2314 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質量   濃度   体積   分子量 *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます:C1V1 = C2V2

    濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    最近チェックした製品:

    オンラインお問い合わせ

    Your information is safe with us. * Required Fields.

    製品名

     

    カスタマ需要量 *

    お名前 *

     

    タイトル

    メールアドレス *

     

    電話番号 *

    デパートメント

     

    組纖名 *

    市区町村

    都道府県

    国或いは地域 *

         

    必ず会社名を記載ください。個人への返信は行いません。

    備考

    バルクお問い合わせ

    Inquiry Information

    製品名:
    Barasertib-HQPA
    製品番号:
    HY-10126
    数量:
    MCE 日本正規代理店: